LUMIGAN

LOE Approaching

bimatoprost

NDAOPHTHALMICSOLUTION/DROPSPriority Review
Approved
Mar 2001
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20

Clinical Trials (5)

NCT05729594Phase 1Completed

Systemic Pharmacokinetic Study of T4032 (Unpreserved Bimatoprost 0.01%) Eye Gel Versus Lumigan® 0.01% Eye Drops in 40 Healthy Volunteers

Started Feb 2023
NCT05397600Phase 3Completed

Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous Patients

Started Jun 2022
NCT04647214N/ACompleted

18 Month Prospective Efficacy and Safety Study of Bimatoprost Intracameral Implant (DURYSTA)

Started Mar 2021
220 enrolled
Open-angle GlaucomaOcular Hypertension
NCT04285580Phase 3Completed

A Phase 3b Study Evaluating the 24-Hour Intraocular Pressure Lowering Effect of Bimatoprost SR in Patients With Open-Angle Glaucoma or Ocular Hypertension

Started Jun 2020
37 enrolled
Open-Angle GlaucomaOcular Hypertension
NCT03891446Phase 3Active Not Recruiting

Long-term Safety and Efficacy Extension Trial of Bimatoprost SR

Started Mar 2019
455 enrolled
Open-Angle GlaucomaOcular Hypertension